Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir in asymptomatic or minimally symptomatic COVID-19 patients
jRCTs041190120Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of favipiravir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Proportion of subjects with clearance of SARS-CoV-2 in nasopharyngeal swab by Day 6. Started Mar 2020; status: completed.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCTs041190120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190120.